Officials at Quality Chemical Industries Limited (QCIL) have called for increased public awareness, early diagnosis and improved access to treatment as Uganda steps up efforts to address the burden of sickle cell disease.
The call was made during the 2026 Annual Sickle Cell Run, organised by the Pharmaceutical Society of Uganda (PSU), which brought together patients, families, healthcare professionals, pharmaceutical companies, policymakers, development partners and members of the public.
The event aimed to raise awareness about sickle cell disease and mobilise resources to support communities affected by the condition.
QCIL Chief Executive Officer Ajay Kumar said the company's participation reflected the growing role of the private sector in supporting public health initiatives, particularly those focused on prevention, early diagnosis, treatment and access to essential medicines.
“To help support the fight against sickle cell disease, we recently launched locally manufactured Hydroxyurea, a development that will improve treatment access, reduce costs and strengthen the country’s pharmaceutical independence,” Kumar said.
Hydroxyurea is widely used in the management of sickle cell disease. While it is not a cure, the medicine can help reduce the frequency and severity of complications associated with the condition, including painful crises and other health problems.
Kumar said local production of Hydroxyurea should be viewed not only as a pharmaceutical milestone but also as part of broader efforts to strengthen Uganda's capacity to respond to long-term public health challenges.
